Association between IL6 gene polymorphism and the risk of chronic obstructive pulmonary disease in the north Indian population

Document Type: Short communication


1 Department of Biotechnology, Panjab University, Chandigarh-160014, India

2 Assistant Professor, Dept. of Biotechnology, SUSCET, Tangori, Punjab-140306, India

3 Respiratory Medicine, MMCH, Solan, Himachal Pradesh, India


Interleukin-6 (IL6) is encoded by the IL6 gene in human and acts as pro-inflammatory cytokine and an anti-inflammatory cytokine. Recent studies established that IL6 substantially contribute in the diagnosed of systemic inflammation for the patients suffering from lung diseases such as chronic obstructive pulmonary disease (COPD). Thereof, this work aimed to investigate the protagonist of IL6 (-174 G/C) genotypes as an essential risk factor for COPD in north Indian population. In the study, a total of 200 clinically diagnosed patients with COPD were selected against 200 patients. Statistical analysis reveleaed that there was no significant association between the  IL6 -174 G/C genetic polymorphism and the risk of COPD (P>0.05).


1. Su YC, Jalalvand F, Thegerstrom J, Riesbeck K. The interplay between immune response and bacterial infection in COPD: Focus upon non-typeable haemophilus influenzae. Front Immunol  2018;9:2530.
2. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease  report: GOLD executive summary. Arch Bronconeumol 2017;53:411-412.
3. Rossi A, Butorac-Petanjek B, Chilosi M, Cosio BG, Flezar M, Koulouris N, Marin J, Miculinic N, Polese G, Samaržija M, Skrgat S, Vassilakopoulos T, Vukić-Dugac A, Zakynthinos S, Miravitlles M. Chronic obstructive pulmonary disease with mild airflow limitation: current knowledge and proposal for future research-a consensus document from six scientific societies. Int J Chron Obstruct Pulmon Dis 2017;12:2593-2610.
4. Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, Jonsson E,  Larsson LG, Andersson S, Sandstrom T, Larsson K. Not 15 but 50% of smokers develop COPD?-Report from the obstructive lung disease in northern Sweden studies. Respir Med 2003;97:115-122.
5. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease.  J Allergy Clin Immunol 2016;138:16-27.
6. Gubernatorova EO, Gorshkova EA, Namakanova OA, Zvartsev RV, Hidalgo J, Drutskaya MS, Tumanov AV, Nedospasov SA. Non-redundant functions of IL-6 produced by macro-phages and dendritic cells in allergic airway inflammation. Front Immunol 2018;9:1-14.
7. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21:1248-1257.
8. Kirtipal N, Thakur H, Sobti RC. Insertion/deletion polymorphism of angiotensin-converting enzyme and chronic obstructive pulmonary disease: A case-control study on north Indian population. Mol Biol Res Commun 2019;8:167-170.
9. Sery O, Hladilova R, Novotny M, Hribkova H, Znojil V, Zvolsky P. Association between-174G/C polymorphism of interleukin-6 gene and alcoholism. Acta Neuropsychiatr 2003; 15:257-261.
10. Seifart C, Dempfle A, Plagens A, Seifart U, Clostermann U, Muller B, Vogelmeier C, Von Wichert P. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens  2005;65:93-100.
11. Cordoba-Lanus E, de-Torres JP, Lopez-Aguilar C, Rodriguez-Perez MC, Maca-Meyer N, Montejo-de-Garcini A, Aguirre-Jaime A, Pérez-Méndez L, Casanova C. Association of IL-6 gene polymorphisms and COPD in a Spanish population. Respir Med 2008;102:1805-1811.